OTCMKTS:SVNTQ Savient Pharmaceuticals (SVNTQ) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free SVNTQ Stock Alerts Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume340,036 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Savient Pharmaceuticals alerts: Email Address Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About Savient Pharmaceuticals Stock (OTCMKTS:SVNTQ)Savient Pharmaceuticals, Inc. (Savient), incorporated in 1980, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. In October 2013, the Company announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court). Effective January 10, 2014, Crealta Pharmaceuticals LLC, a majority owned unit of GTCR LLC acquired Savient Pharmaceuticals Inc.Read More Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> SVNTQ Stock News HeadlinesMarch 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics on Strong Phase 3 Results for Anaphylm™ with Raised Price TargetMarch 5, 2024 | nasdaq.comQuoin Pharmaceuticals Prices Offering Of Approx. 4.1 Mln Shares At $1.6/Share; Stock TanksApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!March 4, 2024 | msn.comCrude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike HigherFebruary 12, 2024 | markets.businessinsider.comCorvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory DiseasesFebruary 2, 2024 | reuters.comIndia's Torrent Pharma posts higher Q3 profit on strong domestic demandJanuary 19, 2024 | businesswire.comDevonian Seeks Shareholders Approval for Share ConsolidationJanuary 16, 2024 | msn.com4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn’t One.April 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!January 4, 2024 | tmcnet.comSail Biomedicines Appoints Tech and Pharma Industry Veteran Frank D'Amelio to Its BoardJanuary 4, 2024 | benzinga.comThe Analyst Verdict: Rhythm Pharmaceuticals In The Eyes Of 7 ExpertsDecember 9, 2023 | tmcnet.comCorvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialDecember 7, 2023 | msn.comAbbVie Makes Another Big Pharma Acquisition. How It’s Putting Its Cash to Work.November 28, 2023 | benzinga.comFosun Pharma USA Announces Abstract to be Presented at IASLC 2023 North America Conference on Lung Cancer (NACLC)October 22, 2023 | investing.comSavient Pharmaceuticals Inc (SVNT)October 3, 2023 | businesswire.comPharma Logistics Awarded Department of Defense Contract for Pharmaceutical Reverse Distribution ServicesOctober 2, 2023 | benzinga.comDisposition of Common Shares of Small Pharma Inc.September 30, 2023 | msn.comLife Pharma inks distribution pact with pharmaceutical major PharmEvo of PakistanSeptember 29, 2023 | benzinga.comAnnexin announces success in the company's cancer initiativeSeptember 18, 2023 | technews.tmcnet.comAvalyn Pharma's CEO Leads Workshop on Clinical Strategy at IPF SummitSeptember 16, 2023 | marketwatch.comScinai Immunotherapeutics Shares Fall Premarket After Stock Offering >SCNIAugust 6, 2023 | msn.comUSFDA issues warning letter to Intas Pharma for Sanand plantAugust 3, 2023 | markets.businessinsider.comTerns Pharmaceuticals (TERN) Receives a Buy from Mizuho SecuritiesAugust 3, 2023 | technews.tmcnet.comQuoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial ResultsAugust 2, 2023 | news.yahoo.comWhat to know about Manitowoc's first Narcan vending machineJuly 24, 2023 | benzinga.comABVC BioPharma Announces Reverse Stock SplitApril 1, 2023 | thestreet.comSavient Stock Hits New 52-Week Low (SVNT)See More Headlines Receive SVNTQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savient Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:SVNTQ Previous SymbolNASDAQ:SVNT CUSIPN/A CIK722104 Webwww.savientpharma.com Phone+1-732-4189300FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report SVNTQ Stock Analysis - Frequently Asked Questions How do I buy shares of Savient Pharmaceuticals? Shares of SVNTQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SVNTQ) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savient Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
